Pablo G. Legorreta - 11 Feb 2026 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role
CEO, Chairman of the Board, Director
Signature
/s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta
Issuer symbol
RPRX
Transactions as of
11 Feb 2026
Net transactions value
$0
Form type
4
Filing time
13 Feb 2026, 16:03:47 UTC
Previous filing
07 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Legorreta Pablo G. CEO, Chairman of the Board, Director C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK /s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta 13 Feb 2026 0001507678

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Award $0 +157,828 +17% $0.000000 1,098,783 11 Feb 2026 Direct F1
holding RPRX Class A Ordinary Shares 1,040,410 11 Feb 2026 By Legorreta Children 2002 Trust
holding RPRX Class A Ordinary Shares 901,590 11 Feb 2026 By GST-Exempt Legorreta 2012 Family Trust
holding RPRX Class A Ordinary Shares 600,000 11 Feb 2026 By Legorreta 2023 SR Trust
holding RPRX Class A Ordinary Shares 460,139 11 Feb 2026 By Legorreta Investments LLC
holding RPRX Class A Ordinary Shares 292,190 11 Feb 2026 By Tata MC 35 Ltd.
holding RPRX Class A Ordinary Shares 123,310 11 Feb 2026 By IRRA
holding RPRX Class A Ordinary Shares 118,500 11 Feb 2026 By SEP/IRA
holding RPRX Class A Ordinary Shares 41,306 11 Feb 2026 By GST-Exempt Legorreta 2020 Family Trust
holding RPRX Class A Ordinary Shares 10,000 11 Feb 2026 By Son
holding RPRX Class A Ordinary Shares 10,000 11 Feb 2026 By Daughter
holding RPRX Class A Ordinary Shares 6,930 11 Feb 2026 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 73,495,660 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 13,356,742 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.